Enlivex Market Capitalization from 2010 to 2025

ENLV Stock  USD 1.03  0.03  3.00%   
Enlivex Therapeutics Market Cap yearly trend continues to be fairly stable with very little volatility. Market Cap is likely to outpace its year average in 2025.
Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 15.3 K, Total Revenue of 0.0 or Research Development of 23.2 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.82. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enlivex Therapeutics Correlation against competitors.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Latest Enlivex Therapeutics' Market Capitalization Growth Pattern

Below is the plot of the Market Cap of Enlivex Therapeutics over the last few years. It is Enlivex Therapeutics' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enlivex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 26.39 M10 Years Trend
Pretty Stable
   Market Cap   
       Timeline  

Enlivex Market Capitalization Regression Statistics

Arithmetic Mean55,002,349
Geometric Mean44,574,589
Coefficient Of Variation53.00
Mean Deviation18,511,616
Median55,071,958
Standard Deviation29,153,871
Sample Variance849.9T
Range104.3M
R-Value0.19
Mean Square Error878.2T
R-Squared0.04
Significance0.48
Slope1,155,626
Total Sum of Squares12749.2T

Enlivex Market Capitalization History

202550.2 M
202445.1 M
202350.2 M
202272.5 M
2021111.6 M
2020111 M
201972.6 M

About Enlivex Therapeutics Financial Statements

Enlivex Therapeutics investors use historical fundamental indicators, such as Enlivex Therapeutics' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. Enlivex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 71 people.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.